Screening of FDA approved drugs for finding potential inhibitor against Granzyme B as a potent drug-repurposing target

Publication date: Available online 11 October 2019Source: Journal of Molecular Graphics and ModellingAuthor(s): Saima Ikram, Jamshaid Ahmad, Serdar DurdagiAbstractGranzyme B is one of the best-characterized and extensively studied members of cytotoxic lymphocytes (CL) proteases. Initially is thought to be involved in eliminating virally infected or cancerous cells by using a specialized mechanism through which they are internalized into target cells. In the last decade, however this dimension has changed as there are several reports show that not only CL but also other immune cells can also synthesize Granzyme B. This leads to the possibility of the presence of these proteases in extracellular environment. Being active protease, it then raises the possibility of damaging host tissues as evident from the available reported literature. In many instances, Granzyme B is directly involved in pathogenicity, however in others, it contributes to the disease severity as their over expression makes the clinical situation quite worse which ultimately leads to the chronic state of the disease. Serine protease inhibitor-9 is a natural known intracellular inhibitor of Granzyme B, however there is less data available about the potential inhibitors that can regulate their activity in an extracellular environment. Current study is an effort to identify potential novel inhibitors of Granzyme B. For this aim, drug repurposing study was performed. Around 7900 FDA approved drugs were screened usi...
Source: Journal of Molecular Graphics and Modelling - Category: Molecular Biology Source Type: research